Implantation of Artiflex phakic IOL for high myopia: effectiveness of the procedure after 24 month follow-up

Session Details

Session Title: Interactive Free Paper Session: Anterior chamber phakic IOLS

Session Date/Time: Tuesday 16/09/2014 | 16:30-18:00

Paper Time: 16:42

Venue: Auditorium

First Author: : F.Faria-Correia PORTUGAL

Co Author(s): :    T. Monteiro   N. Franqueira   K. Sousa   R. Leite   J. Mendes   F. Vaz

Abstract Details

Purpose:

To evaluate the effectiveness of phakic iris-claw IOL surgery for correction of high myopia after 24-month follow-up.

Setting:

Ophthalmology department, Hospital de Braga, Braga - Portugal

Methods:

Retrospective study of patients that underwent phakic iris-claw IOL (Artiflex®, Ophtec BV, Groningen, The Netherlands) implantation for high myopia correction. Preoperative and 24-month follow-up data were analyzed regarding the best-corrected visual acuity (BCVA), spherical and cylindrical refractions and keratometry. Cylindrical refraction was converted to the corneal plane equivalent using the Muñoz-Escrivá equation. The Effectiveness and Safety Indexes of the procedure were also calculated.

Results:

We included 45 eyes (22 OD and 23 OS) implanted with Artiflex® phakic IOL. Mean age was 32.48±7.63 years old. There was a significant improvement in BCVA using decimal scale: 0.73 to 0.94 (p<0,001). Spherical equivalent underwent an important improvement of -10.0D to -0.24D (p<0.001). The Effectiveness Index was 1.14±0.52 and the Safety Index was 1.30±0.58. Astigmatic vectors obtained statistically significant differences on B vector (p<0.001) and C45 vector (p<0.05), but not significant on C0 vector. For keratometry measurements, there was no statistically significant difference (p<0,001) between pre and postoperative data.

Conclusions:

Phakic iris-claw IOL is an effective option for high myopia treatment. Twenty-four months after implantation of the phakic iris-claw IOL, patients had significantly reduced spherical equivalent and refractive cylinder, showing also good visual outcomes.

Financial Interest:

NONE